Table 2.
The application of BTZ in clinics and clinical trials.
| Disease | Regimen | Status | Outcomes |
|---|---|---|---|
| MCL | VCR-CAVD | Approved | CR 68%, ORR 95%, three-year PFS 72% |
| MM | BTZ | Approved | one-year survival was 80%, CR 6%, PR 38% |
| WM | BDR | Phase II | CR 3%, PR 58%, PFS 42 months, three-year survival rate 81% |
| WM | BER | Phase I/II | CR 5.6%, PR 47.2%, PFS 21 months |
| DLBCL | R-CHOP+BTZ | Phase II | ORR 88%, CR/Cru 75%, two-year overall survival rate 70%, two-year progression-free survival rate 64% |
| PTCL | CHOP+BTZ | Phase II | ORR 76%, CR 65%, three-year overall survival rate 47%, PFS 35% |
| AML | BTZ+idarubcin+ cytarabine | Phase II | The overall effective rate 83% CR 58% |
| Breast cancer | BTZ+ pegylated liposomal doxorubicin | Phase II | PR 8%, median overall survival 4.3 months |
| Lung cancer | BTZ+ docetaxel | Phase II | One-year survival was 33%, Disease control rates were 54% |
Abbreviations: WM: Waldenstrom’s Macroglobulinemia; DLBCL: Diffuse Large B-cell Lymphoma; PTCL: Peripheral T-cell Lymphoma; AML: acute myelogenous leukemia; BDR: BTZ, dexamethasone and rituximab; BER: BTZ, everolimus and rituximab; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; CR: complete response rate; PFS: progression-free survival; ORR: overall response rate; PR: partial response.